Multiple Myeloma Hub continues to provide the latest treatment and research updates in the field of myeloma during Q4

Press release: Available for immediate release

The Multiple Myeloma Hub, run by Scientific Education Support (SES) in partnership with the European School of Haematology (ESH), is an open-access online resource dedicated to providing balanced, reliable, and up-to-date medical education in multiple myeloma (MM). During the last quarter of 2021, we continued to promote significant developments in the treatment of MM through our coverage of three international congresses.

We attended two congresses virtually—the Lymphoma, Leukemia, and Myeloma Congress, held on October 19–23, 2021, and the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies, held on October 21–24, 2021. We were delighted to be able to attend the 63rd American Society of Hematology Annual Meeting & Exposition (ASH 2021) in person on December 11–14, 2021, in Atlanta, Georgia. At these congresses we provided extensive live Twitter coverage, expert interviews across key clinical topics, and written summary articles on key talks relating to MM.

In Q4, the Multiple Myeloma Hub also held its second steering committee meeting of the year, with a new and improved format. We discussed the key educational gaps in MM, and our steering committee provided us with some great topics to expand on these unmet educational needs, such as national/country-specific guidelines and lessons learned from COIVD-19, as well as many other topics.

The Multiple Myeloma Hub would like to thank its supporters—Pfizer, Sanofi, AbbVie, Bristol Myers Squibb, Genentech, Roche, Amgen, Oncopeptides, Takeda, and Karyopharm Therapeutics—without whom the platform would not be possible.

Reviewing the Multiple Myeloma Hub’s impact this quarter, Mia Hill, IME Director at Scientific Education Support, said:

“We were pleased to see the hub continue to grow, with just under 12,000 new users to the hub this quarter. It’s also very encouraging to see that our new steering committee meeting format was well received and indeed proved inciteful; the articles covering the topics picked by the steering committee, including the ‘Treatment pathways and patient attrition across lines of therapy: The French experience’ and ‘COVID-19 lessons learnt in patients with multiple myeloma’, were well received.

Our steering committee also provided us with their recommendations on the important sessions from ASH 2021. Be sure to read our ‘ASH 2021 abstracts: What’s hot in multiple myeloma?’ summary, and stay tuned for further information on the top changes in treatment management for patients with MM.”

ENDS

For more information on the Multiple Myeloma Hub, please visit multiplemyelomahub.com.

For media enquiries or to explore collaboration opportunities, please contact secretariat@scientificeducationsupport.com or Barry.Connolly@scientificeducationsupport.com.

NOTES TO EDITOR

About multiple myeloma (MM)

Multiple myeloma (MM) is a form of blood cancer that begins with aberrant plasma cells—a type of white blood cell—in the bone marrow. It's called MM as it frequently affects several bones in the body, including the spine, skull, pelvis, and ribs, preventing the bone marrow from producing enough healthy blood cells while damaging and weakening the affected bones. MM accounts for 15% of all blood malignancies and 2% of all cancers.

About the Multiple Myeloma Hub

The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MM. Our aim is to enhance knowledge of MM through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.

The Multiple Myeloma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Informed by patients, curated by world leaders, and endorsed by expert societies, the Multiple Myeloma Hub supports HCPs worldwide.

Founded in partnership with the European School of Haematology (ESH) in 2017, the Multiple Myeloma Hub is guided by an international steering committee of experts in the field of MM. The steering committee meet regularly to discuss the performance of the Multiple Myeloma Hub and to devise action plans on how best to support the MM community and address any unmet educational needs.

Multiple Myeloma Hub supporters

Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.

• Pfizer
• Sanofi
• AbbVie
• Bristol Myers Squibb
• Genentech
• Roche
• Amgen
• Oncopeptides
• Takeda
• Karyopharm Therapeutics

If you are interested in becoming a Multiple Myeloma Hub supporter, please contact secretariat@scientificeducationsupport.com.

About Scientific Education Support (SES)

SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.

Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology: the ALL Hub, AML Hub, GvHD Hub, Lymphoma Hub, MDS Hub, and MPN Hub.

About the European School of Haematology (ESH)

The European School of Haematology (ESH) is a not-for-profit institution for the dissemination of information and lifelong learning founded in 1985 to promote and facilitate access to state-of-the-art and cutting-edge knowledge in haematology and related disciplines at the European level. ESH conferences present state-of-the-art science and insight into new developments in the fields of basic, clinical and therapeutic research in haematology.